TY - JOUR
T1 - RSV
T2 - perspectives to strengthen the need for protection in all infants
AU - Navarro Alonso, Jose Antonio
AU - Bont, Louis J.
AU - Bozzola, Elena
AU - Herting, Egbert
AU - Lega, Federico
AU - Mader, Silke
AU - Nunes, Marta C.
AU - Ramilo, Octavio
AU - Valiotis, George
AU - Olivier, Catherine Weil
AU - Yates, Ann
AU - Faust, Saul N.
N1 - Funding Information:
The authors thank Martin Friede, Coordinator of the Initiative for Vaccine Research (IVR) at the World Health Organization in Geneva, for his participation as an observer. The authors acknowledge Subhadra Menon, Global Health writer, for providing editorial assistance with the preparation of this manuscript, funded by Sanofi Pasteur and AstraZeneca.
Funding Information:
The authors thank Martin Friede, Coordinator of the Initiative for Vaccine Research (IVR) at the World Health Organization in Geneva, for his participation as an observer. The authors acknowledge Subhadra Menon, Global Health writer, for providing editorial assistance with the preparation of this manuscript, funded by Sanofi Pasteur and AstraZeneca.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/10/21
Y1 - 2021/10/21
N2 - Respiratory syncytial virus (RSV)—the most common viral cause of bronchiolitis—is a significant cause of serious illness among young children between the ages of 0–5 years and is especially concerning in the first year of life. Globally, RSV is a common cause of childhood acute lower respiratory illness (ALRI) and a major cause of hospital admissions in young children and infants and represents a substantial burden for health-care systems. This burden is strongly felt as there are currently no effective preventative options that are available for all infants. However, a renaissance in RSV prevention strategies is unfolding, with several new prophylactic options such as monoclonal antibodies and maternal vaccinations that are soon to be available. A key concern is that health decision makers and systems may not be ready to take full advantage of forthcoming technological innovations. A multi-stakeholder approach is necessary to bridge data gaps to fully utilise upcoming options. Knowledge must be made available at multiple levels to ensure that parents and doctors are aware of preventative options, but also to ensure that stakeholders and policymakers are given the necessary information to best advise implementation strategies.
AB - Respiratory syncytial virus (RSV)—the most common viral cause of bronchiolitis—is a significant cause of serious illness among young children between the ages of 0–5 years and is especially concerning in the first year of life. Globally, RSV is a common cause of childhood acute lower respiratory illness (ALRI) and a major cause of hospital admissions in young children and infants and represents a substantial burden for health-care systems. This burden is strongly felt as there are currently no effective preventative options that are available for all infants. However, a renaissance in RSV prevention strategies is unfolding, with several new prophylactic options such as monoclonal antibodies and maternal vaccinations that are soon to be available. A key concern is that health decision makers and systems may not be ready to take full advantage of forthcoming technological innovations. A multi-stakeholder approach is necessary to bridge data gaps to fully utilise upcoming options. Knowledge must be made available at multiple levels to ensure that parents and doctors are aware of preventative options, but also to ensure that stakeholders and policymakers are given the necessary information to best advise implementation strategies.
KW - Global childhood disease burden
KW - Infant and child health
KW - Infant mortality
KW - RSV, Respiratory syncytial virus
KW - RSV-ALRI, RSV-associated acute lower respiratory illness
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85117729998&partnerID=8YFLogxK
U2 - 10.1186/s12982-021-00104-5
DO - 10.1186/s12982-021-00104-5
M3 - Review article
C2 - 34674730
AN - SCOPUS:85117729998
SN - 1742-7622
VL - 18
JO - Emerging Themes in Epidemiology
JF - Emerging Themes in Epidemiology
IS - 1
M1 - 15
ER -